White label ELPA - ClinicalTrials.eu

Study on Apixaban for Patients with Intrahepatic Non-Cirrhotic Portal Hypertension

Not recruiting

3 1 1
Investigated Drugs:
- Apixaban
Study on Ramucirumab and Paclitaxel for Older Patients with Advanced Stomach Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Gastric cancer
Investigated Drugs:
- Ramucirumab
- Paclitaxel
Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Not recruiting

3 1 1 1
Investigated Diseases:
- HER2 mutant non-small cell lung cancer
Investigated Drugs:
+3
Study on the Safety and Effectiveness of NMD670 for Adults with Charcot-Marie-Tooth Disease Types 1 and 2

Not recruiting

2 1
Investigated Diseases:
- Hereditary motor and sensory neuropathy
Investigated Drugs:
- Nmd670
Study on the Safety and Effects of Vimseltinib for Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

Not recruiting

2 1 1
Investigated Drugs:
- Vimseltinib
Study on Inclisiran and Statin Therapy for Patients with Non-obstructive Coronary Artery Disease to Assess Atherosclerotic Plaque Progression

Not recruiting

3 1 1
Investigated Drugs:
Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Not recruiting

3 1 1
Investigated Drugs:
- Glutamate Decarboxylase 2, Human, Recombinant
- Colecalciferol
+2
Study on the Long-Term Safety and Effectiveness of Filgotinib for Patients with Rheumatoid Arthritis

Not recruiting

3 1 1 1
Investigated Diseases:
- Rheumatoid arthritis
Investigated Drugs:
- Filgotinib
Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Not recruiting

3 1 1 1
Investigated Drugs:
- Adagrasib
- Docetaxel
+8
Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Not recruiting

3 1 1 1
Investigated Diseases:
- Thrombotic thrombocytopenic purpura
Investigated Drugs:
- Caplacizumab
+3

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies